A zonulin test measures levels of a protein that regulates how tightly the cells lining your small intestine are sealed together. When zonulin levels rise, those seals loosen, and the gut becomes more permeable to substances that would normally stay inside the intestinal tract. The test is typically run on a blood or stool sample using an ELISA-based lab kit, and it has gained popularity in functional and integrative medicine circles as a way to assess so-called “leaky gut.” But the science behind the test is more complicated than most patients realize, and the reliability of current commercial assays is a genuine point of contention among researchers.
What Zonulin Does in the Gut
Your intestinal lining is a single layer of cells whose job is to absorb nutrients while keeping bacteria, toxins, and undigested food particles from crossing into the bloodstream. The spaces between these cells are sealed by structures called tight junctions, which act like adjustable gates. Tight junctions are made of proteins that link neighboring cells and anchor to an internal scaffolding, and they can form both a near-total barrier and a selective channel for small ions and water molecules.
Zonulin is one of the body’s own signals for opening those gates. When researchers first discovered it in 2000, they noticed it behaved like a human version of a toxin produced by the cholera bacterium, a toxin known to pry open tight junctions and flood the gut with fluid.1PubMed. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease Later work identified zonulin as the precursor form of a blood protein called haptoglobin-2. In its uncleaved, single-chain state, zonulin contains a molecular motif that activates receptors on the surface of intestinal cells, triggering a signaling cascade that rearranges the cell’s internal skeleton and loosens the tight junction.2PubMed Central. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2 The result is a temporary increase in permeability.
This is not inherently a bad thing. Opening tight junctions briefly is how the body flushes pathogens out of the small intestine and adjusts fluid balance. The problem arises when the signal stays on too long or fires too frequently, keeping the gut chronically permeable and allowing inflammatory molecules to reach tissues they should not reach.
What Triggers Zonulin Release
Two triggers have been well characterized so far. The first is exposure to bacteria in the small intestine. Normally, most of your gut bacteria live in the colon, not the upper small bowel. When bacteria show up higher than they should, the intestinal lining releases zonulin as a defensive flush, regardless of whether the bacteria are harmful or harmless.3Gastroenterology. Intestinal Permeability and Its Regulation by Zonulin: Diagnostic and Therapeutic Implications The second trigger is gliadin, the protein component of gluten. Gliadin binds to a specific receptor on the intestinal surface and prompts zonulin secretion, which then opens the paracellular pathway. This mechanism is particularly pronounced in people with celiac disease, but it also occurs to a lesser degree in people without celiac disease.
Research into additional triggers is still in early stages. Some investigators have looked at environmental stressors. An animal study in dairy cattle, for instance, found that heat stress significantly altered serum zonulin levels, with measurements taken at high ambient temperatures differing from those taken at lower nighttime temperatures.4International Journal of Veterinary and Animal Research. Alterations in Gut Integrity Due to Heat Stress Among Dairy Cattle of Aydin City: Analytical Interpretation of Zonulin Levels Within Repetitive Measurements Whether physiological stress, diet composition, or other environmental factors meaningfully shift human zonulin levels on a day-to-day basis is still an open question, but it raises the practical concern that a single zonulin measurement may fluctuate more than patients expect.
How the Test Is Performed
Most commercially available zonulin tests use a competitive ELISA, a standard immunology lab technique in which your sample competes with a labeled version of the target protein for binding spots on an antibody-coated plate. The more zonulin in your sample, the less labeled protein binds, and the signal changes accordingly. The test can be run on either a blood (serum) sample or a stool sample.5PubMed Central. Calprotectin in serum and zonulin in serum and feces are elevated after introduction of a diet with lower carbohydrate content and higher fiber, fat and protein contents Some clinicians prefer stool-based testing because it reflects what is happening at the intestinal surface without being diluted into the general circulation. Others prefer serum because blood draws are more standardized.
Two of the most commonly used commercial kits come from Immundiagnostik AG in Germany and DRG International in the United States.6PubMed Central. Fecal Zonulin as a Noninvasive Biomarker of Intestinal Permeability in Pediatric Patients with Inflammatory Bowel Diseases—Correlation with Disease Activity and Fecal Calprotectin7Practical Laboratory Medicine. Fecal zonulin is elevated in Crohn’s disease and in cigarette smokers The DRG kit uses polyclonal anti-zonulin antibodies on the plate, adds a biotinylated zonulin tracer that competes with your sample’s zonulin for binding, then detects the bound tracer with a color-changing enzyme reaction. A lab technician reads the color intensity on a spectrophotometer and calculates your zonulin concentration from a standard curve. Results are typically reported in nanograms per milliliter for serum or nanograms per gram for stool.
The Assay Controversy
Here is where the story gets uncomfortable for anyone who has already paid for a zonulin test. Independent researchers have investigated what these commercial ELISA kits actually detect, and the findings are sobering. A 2018 study used mass spectrometry and Western blot analysis with the same polyclonal antibodies packaged in one widely used kit and found that the assay was not detecting prehaptoglobin-2, the protein identified as zonulin, but was instead picking up properdin, a completely different immune protein. The researchers proposed that properdin might itself be a member of a broader “zonulin family,” but the bottom line was that the kit was not measuring what its label said it measured.8PubMed Central. Widely Used Commercial ELISA Does Not Detect Precursor of Haptoglobin2, but Recognizes Properdin as a Potential Second Member of the Zonulin Family
A separate investigation confirmed the problem and went further. When researchers characterized the proteins actually captured by two different commercial zonulin assays, the top hits included haptoglobin and complement C3 for one manufacturer’s kit and complement C3 for the other. Neither kit was reliably detecting the actual zonulin protein as defined by the original research.9PLoS ONE. Serum zonulin as a marker of intestinal mucosal barrier function: May not be what it seems This does not necessarily mean the tests are useless. The proteins they do detect may correlate with intestinal permeability through related pathways. But it means that when your lab report says “zonulin,” it may actually be reporting a mixture of proteins that are not zonulin at all. Researchers now often use the term “zonulin-related proteins” or ZRP to acknowledge this ambiguity.
For patients, the practical implication is straightforward: if the test cannot reliably distinguish the actual zonulin protein from other blood proteins, interpreting your specific number against a reference range becomes shaky. Two patients with identical “zonulin” readings might have very different actual zonulin levels, and no amount of careful interpretation by a clinician can fix a measurement tool that is hitting the wrong target.
What a High Reading Has Been Linked To
Despite the assay limitations, dozens of clinical studies have used these kits to compare ZRP levels between sick and healthy people, and the patterns that emerge are consistent enough to be interesting even if the exact protein being measured is debated.
Celiac disease was the first condition where elevated zonulin was documented. Since then, researchers have found elevated serum ZRP in people with non-celiac gluten sensitivity compared to healthy controls, with levels comparable to those seen in active celiac disease.10PubMed. Serum zonulin and its diagnostic performance in non-coeliac gluten sensitivity In irritable bowel syndrome, both the constipation-predominant and diarrhea-predominant subtypes showed higher zonulin than healthy controls, and in the diarrhea subtype, levels correlated with stool frequency and dissatisfaction with bowel habits.11PubMed Central. Serum zonulin is elevated in IBS and correlates with stool frequency in IBS-D
Inflammatory bowel disease has also shown associations. In a study matching IBD patients to controls, serum ZRP levels were significantly higher in people who already had IBD, but the same elevation was not found in women who went on to develop IBD during follow-up, suggesting ZRP might reflect active disease rather than predict future onset.12PubMed Central. The association of zonulin-related proteins with prevalent and incident inflammatory bowel disease
Outside the gut, the autoimmune connection that has attracted the most attention involves type 1 diabetes. In one study, elevated serum zonulin was detected in roughly 70% of subjects during the period before type 1 diabetes was clinically diagnosed, preceding disease onset by an average of about 3.5 years.13PubMed. Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives The idea is that a chronically leaky gut allows environmental antigens to cross the intestinal barrier and provoke an immune response in genetically susceptible people. This has been extended conceptually to other chronic inflammatory diseases, including metabolic syndrome and some neurological conditions, though most of the evidence for those links remains in early stages.14PubMed Central. All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases
Why There Is No Validated Clinical Diagnosis for “Leaky Gut”
Many patients encounter zonulin testing in the context of a “leaky gut syndrome” evaluation, often ordered by functional medicine practitioners or purchased through direct-to-consumer lab services. It is worth being clear about the medical consensus here: no validated test currently exists to diagnose leaky gut syndrome as a standalone clinical condition.15PubMed Central. Leaky Gut Syndrome: Myths and Management That does not mean intestinal permeability is imaginary. Increased permeability is a measurable physiological phenomenon that accompanies many well-recognized diseases. But there is a gap between “intestinal permeability is a real thing that changes in disease” and “there is a reliable blood or stool test that can diagnose it in a doctor’s office and guide treatment decisions.”
The traditional research method for measuring intestinal permeability involves swallowing a mixture of sugar probes and then collecting urine over several hours to see how much of each probe crossed the intestinal barrier. This lactulose-mannitol test has been used for decades in research settings and is considered closer to a gold standard for directly measuring permeability. But it is cumbersome, time-consuming, and not widely available in routine clinical labs, which is part of why the simpler blood or stool zonulin test became attractive. The tradeoff is that the simpler test has the assay problems discussed above.
Regulatory Gaps in Consumer Testing
If you have ordered a zonulin test directly from a consumer health company rather than through a physician, there is an additional layer of concern. The regulatory framework for direct-to-consumer microbiome and permeability tests has significant gaps. These tests generally lack proficiency testing requirements under federal lab improvement rules, and the FDA has largely not regulated them as medical devices, viewing them as low-risk general wellness products that fall under software exemptions.16PubMed Central. Is the current regulatory framework for direct-to-consumer microbiome-based tests sufficient to protect consumers from medical, economic, and dignitary harms? This means the kits these companies use, the reference ranges they apply, and the dietary recommendations they bundle with results are not subject to the same scrutiny as tests ordered by your doctor through a certified clinical lab. Some of these services provide genuinely useful information, but you should understand that “lab-tested” does not automatically mean “FDA-validated.”
Can You Lower Zonulin Levels Through Diet or Supplements
Given all the caveats, a fair question is whether you can do anything about a high reading. A growing number of studies have tested dietary and probiotic interventions and measured zonulin as an outcome. A systematic review looking at prebiotics, probiotics, and synbiotics found that these interventions may have favorable effects on serum zonulin levels, though results for other permeability-related markers were mixed and inconclusive.17PubMed Central. The Effects of Prebiotic Dietary Fibers, Probiotics, and Synbiotics on Gut Permeability and Immunity: A Systematic Review A randomized trial testing a probiotic-phytonutrient blend found that fecal zonulin showed a decreasing trend in the intervention groups, with significant reductions specifically in participants who were overweight.18PubMed Central. Effects of Probiotic–Phytonutrient Blends on Defecation, Intestinal Barrier Function, and Gut Microbiota: A Randomized, Placebo-Controlled Trial
On the dietary side, a randomized trial in people with metabolic syndrome found that a short-term calorie-restricted oat diet decreased serum zonulin compared to baseline. The zonulin reduction correlated inversely with increases in short-chain fatty acids, particularly butyric acid, suggesting that shifts in gut bacteria and their metabolic output may be part of the mechanism linking diet to barrier integrity.19PubMed Central. Calorie-restricted oat diet is associated with zonulin and short-chain fatty acid response in metabolic syndrome: a randomized controlled trial The practical takeaway from these studies is modest: fiber-rich diets and certain probiotics probably help support the intestinal barrier, but whether tracking zonulin numbers adds anything beyond “eat more fiber and fermented foods” is debatable.
Larazotide Acetate and the Drug Development Angle
If zonulin opens tight junctions, the logical pharmaceutical question is whether you can block it. Larazotide acetate is a synthetic peptide designed to do exactly that. Originally developed as a therapy for celiac disease, it works by inhibiting the rearrangement of the cell’s internal skeleton that occurs when gliadin triggers zonulin release.20PubMed Central. The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate In a large randomized controlled trial involving 340 celiac patients who were already on a gluten-free diet but still symptomatic, the 0.5 mg dose of larazotide acetate reduced symptoms compared to placebo, including roughly a quarter fewer symptomatic days and about a third more improved-symptom days. Higher doses did not show benefit, and the safety profile was similar to placebo.21PubMed Central. Larazotide Acetate for Persistent Symptoms of Celiac Disease Despite a Gluten-Free Diet: A Randomized Controlled Trial
Larazotide has not yet been approved by the FDA for any indication, and its development path has been slower than early enthusiasm suggested. But it matters for the broader zonulin story because it represents the first attempt to pharmacologically target the tight junction pathway. If this or a similar drug eventually reaches the market, having a reliable test for the pathway it targets would become much more clinically relevant. Right now, the test and the drug are both works in progress.
Cigarette Smoking and Unexpected Associations
One finding that catches people off guard is the connection between cigarette smoking and fecal zonulin. A study comparing IBD patients and healthy controls found that fecal zonulin was elevated not only in Crohn’s disease but also in smokers among the healthy control group.7Practical Laboratory Medicine. Fecal zonulin is elevated in Crohn’s disease and in cigarette smokers Smoking is already known to have widespread effects on gut inflammation and microbiome composition, so it is not entirely surprising that it might also affect barrier integrity. But it underscores how many variables can shift a zonulin result. If you are a smoker getting a zonulin test to evaluate food sensitivities, the smoking itself may be driving part of the signal, and no amount of dietary modification will address that particular contributor.
More broadly, the number of factors that can influence intestinal permeability on any given day, including stress, medications like nonsteroidal anti-inflammatory drugs, alcohol, sleep deprivation, and intense exercise, means that a single-timepoint zonulin measurement captures a snapshot that may not represent your baseline state. Researchers working with zonulin data often collect repeated measurements and control for confounders. A one-off test from a consumer lab does not have that luxury.
When Zonulin Testing Might Actually Be Informative
None of this means zonulin testing is worthless in every context. In research settings, tracking ZRP levels over time within the same person, using the same assay, can reveal trends that correlate with disease activity or treatment response. The pediatric IBD study that measured fecal zonulin alongside calprotectin, a more established inflammatory marker, was looking for exactly this kind of paired-biomarker approach.6PubMed Central. Fecal Zonulin as a Noninvasive Biomarker of Intestinal Permeability in Pediatric Patients with Inflammatory Bowel Diseases—Correlation with Disease Activity and Fecal Calprotectin If future assays are developed that actually detect prehaptoglobin-2 specifically, or if the “zonulin-related proteins” that current kits detect are validated as a distinct biomarker class with their own clinical cutoffs, the test could become genuinely useful.
For now, a reasonable position is that a high zonulin result should not be treated as a diagnosis of anything, but it can serve as one piece of a larger clinical picture when combined with symptoms, other lab markers, and a thorough history. If a practitioner orders a zonulin test and then builds an entire treatment plan around the number alone, that is a red flag about the practitioner, not a statement about your gut health.